Quest Diagnostics Stock (NYSE:DGX)
Previous Close
$163.99
52W Range
$125.42 - $178.87
50D Avg
$168.53
200D Avg
$156.50
Market Cap
$18.75B
Avg Vol (3M)
$1.30M
Beta
0.78
Div Yield
$3.05 (1.82%)
DGX Company Profile
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
DGX Performance
Peer Comparison
Ticker | Company |
---|---|
TWST | Twist Bioscience Corporation |
WAT | Waters Corporation |
MTD | Mettler-Toledo International Inc. |
ICLR | ICON Public Limited Company |
IQV | IQVIA Holdings Inc. |
A | Agilent Technologies, Inc. |
RVTY | Revvity, Inc. |
IDXX | IDEXX Laboratories, Inc. |
CRL | Charles River Laboratories International, Inc. |
SHC | Sotera Health Company |